Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2025

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

Crohn’s and Colitis 2025 Advance Access: 13 July 2025 Doi: 10.1093/ecco-jcc/jjaf124

Wu J,

Zhu B,

Moses R,

Mirikizumab was evaluated for its ability to achieve disease clearance (DC) across two years in adults with moderately to severely active ulcerative colitis within the LUCENT trial programme. DC required concurrent symptomatic, endoscopic, and histologic remission.

Keywords:

May 2025

The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm

Lancet Rheumatol 2025;7: e314–22 DOI: 10.1016/S2665-9913(24)00312-6

Maksymowych WP,

Lambert RGW,

Bolce RJ,

Bello N,

Zhu B,

Lisse JR,

Østergaard M

Maksymowych et al. evaluated the effect of ixekizumab and adalimumab versus placebo over 52 weeks on structural lesions in sacroiliac joints assessed by MRI in patients naive to biological DMARDs with radiographic axSpA from the COAST-V study. The authors reported a decrease in erosion and increase in backfill at Week 16 with further reductions in erosion and increases in backfill occurring at Week 52 in patients receiving ixekizumab.